Health
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
PRINCETON, N.J., December 19, 2025--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/633243bc2a5b80438ac17d49355ca907"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6RoBRwiylrqoNaXNs4uA0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/633243bc2a5b80438ac17d49355ca907","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ucyRUIn53apCyOaffn030Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/633243bc2a5b80438ac17d49355ca907","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"Agreement Provides Tariff Relief for a 3-Year Period","length":52,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., December 19, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") today announced an agreement with the U.S. government to provide Eliquis® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for free to the Medicaid program and to donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to ensure American supply chain resilience. The agreement is aligned with BMS’s ongoing commitment to advancing cardiovascular health, improving patient outcomes and collaborating with policymakers on solutions that lower costs for American patients and the healthcare system without jeopardizing future innovation.","length":688,"tagName":"p"},{"type":"text","content":""We are taking direct action to improve the lives of millions of Americans, ensuring our nation’s most vulnerable have access to this critical medicine at no cost," said Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb. "Today’s agreement builds on BMS’s efforts to improve affordability, increase transparency and continue to invest in America, where we have an over 165-year history of discovering and developing life-changing medicines."","length":483,"tagName":"p"},{"type":"text","content":"Eliquis is the most widely prescribed oral ...